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ABSTRACT 
Varied facets of health and disease are networked in molecular biologic and physiologic mechanisms which are explored and 
understood only partly. The later task is formidable challenge for interdisciplinary biomedical research, particularly in respect to 
cancer. The mystical/divine coding for individual life span may be scientifically decoded amid biological networks. Trade-offs 
between cancer and other infirmities provide for reorganizing holistic medical thought with better objectivity. Bits of cumulated, 
traditional, and reductionist knowledge needs holistic interpretation to meet such goal. How medical strategies may selectively 
negotiate the networks to fetch benefit without becoming counter-productive, is major question. Available information on biological 
basis of trade-offs between cancer and ageing is briefly discussed. That has crucial implications to concept and design of preventive 
and remedial interventions, particularly, drugs. 
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INTRODUCTION: The Trade-Off  
Human organism undergoes influence of factors promoting both 
positive and negative correlations among diseases. Comorbity 
patterns develop as per the duration and level of exposures to such 
factors during certain periods of individual’s life. Understanding 
of ageing related decline in human health/well-being , and 
evaluation of interventions aiming at increasing healthy longevity 
necessitates study of such factors and their mechanisms of action 
.Ageing linked chronic diseases have crucial implications to 
strategies increased life span by reducing cancer risk. Cellular 
mechanisms of tumor suppression, e.g. senescence and 
programmed cell death (apoptosis), also enhance ageing as 
indicated in experiments (1). Higher cancer risk is implied in 
increased longevity of population. Treatment of one disease may 
increase susceptibility to other diseases. In such “trade off”, 
certain factors favoring cancer increase longevity and are 
protective against age-linked diseases, unless cancer actually 
occurs. Hence, eradication of cancer risk simply would prolong 
lifespan. Bearing of induced delay in some fundamental ageing 
process and prevention of chronic diseases and other disease risks, 
to longevity deserves better understanding. A trade-off indicates 
that longevity may be increased by changing balance with 
infirmities negatively correlated in regard to mortality risks. 
Strategy for Epidemiologic Studies and Cholesterol /Cancer 
Relation  
“Dependant competing risk paradigm” suits as approach for 
epidemiological investigation of connection among diseases. 
Rothenberg, adopting such approach revealed that reduction in 
cardiovascular disease related mortality, increases cancer related 
mortality (2), which makes prediction of age specific increase of 
cancer risk difficult among older persons. Effect of changes in 
physiological and other variables affecting disease risks need due 
accounting (3). Merit of strategies to lower cholesterol in 
population remains debated (4). A, U shaped association among 
men indicates a higher total mortality rate for those with high as 
well as with low serum cholesterol (5). While 
hypercholesterolemia is established principal risk factor for 
coronary heart disease, lower cholesterol profile increases risk of 
cancer and non-coronary cardiac deaths (6-8). Possibilities exist 
that such association is secondary to confounding factors such as, 
serum retinol, vitamin E and beta carotene (9-12). The population 
includes people with genetically low concentrations as well as 
those with acutely or chronically depressed cholesterol as a result 
of inflammation, cancer or other diseases (7,13). How low 
cholesterol would increase cancer risk remains unsettled. 
Cholesterol may be promoter not initiator of carcinogenesis, as a 
risk factor and lower concentration limits that increase cancer are 
not settled. Serum cholesterol profiles correlated inversely with 
subsequent cancer related mortality in a Puerto Rican study (14). 
Relative weight, ventricular rate, haematocrit and cigarette 
smoking, made independent contributions in certain age groups. 
Such association was not seen in women (15). The gender based 
differences may be due to hormonal or metabolic mechanisms. An 
inverse association among centrally obese women and a positive 
association among peripherally obese women were found by 
Kritchevsky (16). 
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Several biological mechanisms have been proposed to explain 
inverse association between serum cholesterol and cancer 
mortality. A persons lipoprotein cholesterol profile is significantly 
associated with his predisposition to develop cancer, as shared 
genetic factor may presumably be involved (17). Low cholesterol 
levels may enhance carcinogenesis by affecting integrity of 
cellular membrane (18). Cruse et al (19), suggested that 
cholesterol may exert a conditional influence, acting indirectly via 
hormonal or immunologic mechanism. Also it may promote the 
action of an already initiated carcinogenic process. The biologic 
mechanism needs further research to reveal. Oxidised low density 
lipoprotein cholesterol (LDL), affects many of the biologic events 
that occur during development of atherosclerotic lesions (20). 
Some oxLDL formed early, may influence gene expression. LDL 
that enters sub-endothelial space by transcytosis undergoes mild 
oxidative changes mediated by endothelial cells. It then stimulates 
expression of genes, e.g. endothelial adhesion molecules, 
chemotactic factors and colony stimulating factors, which result in 
attraction, retention, maturation and activation of monocytes, 
macrophages or T Lymphocytes. LDL oxidation is involved in 
mediating atherogenic risk of cigarette smoking, diabetes mellitus 
and atherogenic lipoprotein phenotype, characterized by the 
presence of small dense LDL (21). The adipose tissue is endocrine 
organ and plays important role in regulating energy metabolism 
and inflammation (22). Significance of lipid and its novel 
constituents e.g. Adiponectin, IgG and IgM types of 
autoantibodies to oxidized LDL (oxLDLIgG and oxLDLIgM), has 
been established in relation to cardiovascular disease (23,24). 
These may be considered biomarkers of lipid peroxidation (25). 
The oxLDL is toxic to endothelium and smooth muscle of arterial 
wall and is monocyte chemotractant (26). Markers of 
atherosclerotic vascular diseases show positive correlation with 
levels of oxLDLIgG (27). In contrast, protective role for 
oxLDLIgM in human cardiovascular diseases is proposed. 
Cholesterol and Carcinogenesis: 
Lipid peroxides damage DNA and can seriously impair repair 
capacity by direct interaction with repair proteins (28). 
Furthermore, they influence the intracellular redox equilibrium 
affecting several crucial signal transduction pathways (29). 
Adiponectin, serum immunoglobulinG, immunoglobulinM 
antibodies versus oxLDL levels (oxLDLIgG;oxLDLigM), may 
play role in development and progression of various types of 
malignancies (23,30,31). Excess lipid peroxidation including 
oxLDL and anti-oxLDL auto-antibodies indicating oxidative 
stress, are believed to play key role in cancer development 
(27,32). Lower oxLDLIgG levels predicted decreased risk of 
acute myeloblastic leukaemia (AML), while higher oxLDLIgM 
predicted increased risk of AML. Low serum levels of oxLDL 
antibody can lead to uncontrolled cellular proliferation and 
reduction of apoptosis. Both such effects contribute to 
carcinogenesis. In contrast to their relation with cardiovascular 
and cerebro-vascular diseases, descending levels of oxLDL and 
oxLDL antibodies negatively correlate to different stages of 
esophageal cancer development. The elevation in oxLDLIgM had 
a positive potence (33). Another study by Eichholzer et al (34), 
revealed that increased mortality risk from cancer associated to 
low plasma cholesterol cannot be explained by confounding effect 
of antioxidant vitamins. The biological mechanism underlying the 
findings, the role of other risk factors of leukaemia e.g. smoking 
and exposure to certain chemicals are necessary to reveal. 
Whether oxLDLIgG as well as oxLDLIgM play causal role or 
mere consequential role in AML may be ascertained for 
contemplating preventive and therapeutic interventions. 
arNOX and Its Role 
Age related NADH oxidase, (arNOX), are proteins that appear in 
cells and serum only after age of 30, rising thereafter to age of 
maturity in sixties and seventies (35). Five members of the TM-9 
transmembrane protein family have origin from codes on different 
chromosomes. arNOX reduce molecular oxygen to superoxide 
anion and also to water. arNOX are shed from cell surface in to 
circulation generating superoxide and oxidizing serum 
lipoproteins (36,37). Reactive oxygen species are responsible for 
circulating oxidized LDL, and their clearance by macrophages 
through delivery to arterial wall (38). Eventually, atherosclerosis 
results advancing heart disease, arterial blockage, stroke and 
death. 
The arNOX proteins, by generating superoxide and ROS, in direct 
contact with circulating lipoproteins as an electron source, are 
crucial contributor to cardiovascular disease. The arNOX provides 
a mechanism to transmit oxidative changes on cell surface to 
surrounding cells and circulating lipoproteins. Constitutive cell 
surface arNOX proteins, capable of oxidizing reduced quinones, 
can formulate a complete chain of electron transport from cytosol 
to oxygen at cell surface, with these proteins serving as terminal 
oxidases. These link accumulation of lesions in the mitochondrial 
DNA to cell surface accumulation of ROS, as one consequence of 
their stated role. By their location on cell surface (with capability 
to form superoxide in response to ageing), arNOX serve to 
propagate the ageing cascade to adjacent cells. The arNOX are 
inhibited by oxidized coenzyme Q (37). Coenzyme Q is obvious 
circulating molecule preventing ageing related oxidative changes 
in cell membrane and lipoproteins. Use of dietary coenzyme Q 
should be rational means to retard age related arterial lesions (36). 
The arNOX activity that increases susceptibility to atherosclerotic 
heart disease plays protective function against cancer, serving as 
key to the negative correlation between cancer and heart disease. 
The oxidized LDLs trigger apoptosis in collaboration with 
scavenger receptors and Toll like receptors (39-41). The state 
favors formation of foam cells, contributing to atherosclerosis. 
The heightened activity of arNOX results in increased apoptosis 
and autophagy, both processes being un-favourable to 
carcinogenesis. 
Autophagy 
Autophagy is inherent pathway in all such cells that contain 
lysosomal compartment, which carries out turnover of long lived 
proteins and cell organelles, also remodeling cytoplasm (42-44). 
Autophagy, is a cell response to stress, and can cause cell death 
under certain circumstances. Autophagic cell death is termed, 
type-II programmed cell death to distinguish it from apoptosis, 
and termed as type I programmed cell death (45). Autophagy is 
stimulated by stress, e.g. Starvation, change in cell volume, 
oxidative stress, accumulation of misfolded proteins, hormonal 
signals, irradiation, xenobiotics etc. In mammals, autophagy 
serves anti-aging mechanism by eliminating organelle damaged 
by age associated peroxidation process (46). The protein 
breakdown in autophagy provides amino acids and other elements 
needed for intermediary metabolism and for biosynthetic 
pathways. Amino acids thus regulate the process. Autophagy and 
other lysosomal degradation processes decline during ageing, and 
keeping them active is relevant anti-aging strategy (47). 
Research on biology of ageing has focused on understanding 
molecular controls of autophagy. Several tumor suppressor 
 J. of Advancement in Medical and Life Sciences                  Volume 3/Issue 1                                                     ISSN: 2348-294X 3 
proteins (beclin 1, PTEN phosphatases, tensin homologue deleted 
from chromosome 10) appear to control autophagy. Tumor 
progression would thus be expected to decrease autophagy. A link 
between nutritional environment of cell and G-protein mediated 
control of autophagy exists. Amino acids control activation of 
Raf-1 kinase, leading to inhibition of G-alfa interacting protein 
(GAIF), which regulates G-protein signaling involved in 
autophagy (48). The amino acids are physiological inhibitors of 
autophagy (49). A great variety of stimuli are also able to 
modulate autophagy. Most signaling pathways converge on 
common single target to control autophagy (50). Target receptor 
for Rapamycin TOR, is good candidate as “gate keeper” of 
autophagic pathway. It senses amino acids and ATP. It can also 
integrate hormonal signals via the classI-PI.3 Kinase/Protein 
Kinase B pathway, which also regulate autophagy (51-53). 
Probably, a cyclic AMP-dependant- protein kinase (AMPK) that 
is sensitive to cytosolic AMP/ATP ratio, is involved in controlling 
autophagy (54). AMPK negatively modulates protein synthesis by 
impairing mTOR dependant signaling (55). 
Control of autophagy by class I PI3 Kinase pathway in has 
implications for tumor progression, ageing and cell death. 
Dysregulation of of class I PI3K/PKB signaling is frequent in 
human cancers. Many elements in the later are onco-proteins or 
products of tumor suppressor genes (56-59). Reduced autophagy 
in cancer cells may be a mechanism to survive stress condition 
(50). Cancer cells would overcome limitation of nutrient supply 
by limiting autophagy (60). Autophagic machinery is triggered by 
intracellular aberrations, e.g. protein aggregates in cytosol and 
endoplasmic reticulum and the damaged mitochondria, for their 
recognition and removal. Roles of selective autophagy in cellular 
aging and death may better reveal upon understanding the 
molecular basis and help emergence of therapies for 
mitochondrial pathologies and other aberrations. 
Waiting Research Perspectives 
Aged organism bears modification of epigenome (61). The genes 
“inactivated” in effort to prevent aging prevail in cancers, e.g. 
progeroig genes WRN and laminA/C (62,63). The SirT2 
deacetylase controls cell cycle progression and also supports 
chromosomal stability (64). SirT2 activity displays context 
dependancy in cancer, as per primary molecular target, stress and 
environmental millieu of cell (65,66). Adequate laboratory and 
clinical investigations may resolve the mystery. 
Trade-off between cancer and ageing may reflect opposite 
manifestation of apoptotic and growth signaling pathways in 
cancer and ageing cells, balancing tumor suppression and tissue 
renewal. Tumor suppressor mechanisms e.g. p53 dependant 
induction of senescence and apoptosis, accelerate ageing (67,68). 
Mitochondrial theory, senescence theory and molecular 
inflammation theory are extensively investigated as contributory 
to the aging process (69,70). Interventions to impact lifespan and 
related diseases mandate comprehensive understanding of roles of 
molecular and cellular elements to in-vivo metabolism and 
homeostasis that may optimally be attained in the centenarians. 
Linkage of oncogenes and tumor suppressors to epigenetic 
changes and/or altered metabolism in cancer cells need 
elaboration. Novel alternate metabolic pathways erupting in 
cancer cells indicate dynamic adaptations that intricately relate to 
tumorogenesis as well as progression (71). The role of hypoxia 
inducible key transcription factor and its target genes is seen to 
overlap mechanisms implicated in metabolic disarrays (72,73). 
Such interconnectivity may evolve cancer phenotypes, with 
switching of massive pathways based on the oncogenic 
mechanisms that drive cancer. Sites of dismetabolism can be 
targeted by innovative therapies. 
Cancer vulnerability may trade-off with ageing-unrelated 
infirmities, e.g. myocardial infarct, stroke etc., in which reduced 
apoptosis reduces mortality despite being promoter of cancer risk. 
The consequences of up-regulated programmes of cell death may 
be pro or anti-ageing, as per concurrent presence or absence of 
other ageing related pathologies (1). Normal or enhanced 
apoptosis and postponed-ageing phenotype, characterize 
longevity with reduced cancer risk (74,75). This is classically 
exemplified in “calorie restriction” anti-ageing treatment (76). 
What trade-offs contribute better to longevity, i.e. between cancer 
predisposition and one or other kind of infirmities and why, 
remain largely unexplored, but highly relevant perspectives of 
biomedicine. 
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